Short answer
Health Catalyst, Inc. (HCAT) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). Sale of Vitalware to Med-Metrix for $147 million base price, subject to cash, debt, working-capital and expense adjustments.
Health Catalyst, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Sale of Vitalware to Med-Metrix for $147 million base price, subject to cash, debt, working-capital and expense adjustments
- Expected third-quarter 2026 closing, pending antitrust clearance and acceptance of offers by at least 80% of offered employees
- Proceeds plus cash on hand intended to repay and terminate Health Catalyst’s senior secured term loan, including prepayment premiums
- No Health Catalyst shareholder approval required; transaction may terminate after December 4, 2026, subject to regulatory extension
- Divestiture could materially reshape operations and leverage, but closing and final proceeds remain uncertain
Item 7.01 · Regulation FD Disclosure
- Disclosure concerns proposed Vitalware Business transactions under a Purchase Agreement
- Planned proceeds include repayment and termination of Health Catalyst’s existing senior secured term loan facility
- Completion timeline remains subject to regulatory approval and other closing conditions
- Termination rights and unanticipated transaction costs create execution risk for shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Health Catalyst, Inc. 8-K filings
Get the next HCAT 8-K as it lands
Follow HCAT for push alerts, or ask the research agent what this filing means.